Introduction
The PIM kinases are a family of serine/threonine kinases that regulate cell proliferation and survival (1, 2) and are highly conserved through evolution in multicellular organisms. This family of kinases is composed of three different members (Pim1, Pim2 and Pim3) that are highly homologous at the amino acid level (3), yet differ partially in their tissue distribution (4) . Functional redundancy of the three PIM kinases has been shown in vitro (5, 6) and in vivo (7) .
Unlike other serine/threonine kinases, the PIM family members are tightly regulated at the level of transcription and translation (3) . Their expression is mediated by the JAK/STAT signalling pathway, which is activated by various cytokines and hormones (1, 2, (8) (9) (10) .
The PIM kinase family members are considered oncogenes and have been implicated in tumourigenesis either alone or functioning synergistically with c-Myc (11, 12) . Initially, elevated levels of PIM1 kinase were discovered in leukaemia and lymphoma tumours (13) (14) (15) . However, more recently, PIM1 was found to be increased in solid tumours, including pancreatic and prostate cancer, squamous cell carcinoma, gastric carcinoma, colorectal carcinoma, liver carcinoma (16, 17) and recently liposarcoma (18) . Increased levels of PIM2 kinase have been detected in various lymphomas as well as in prostate cancer. Several in vitro studies also connected PIM2 kinase with liver cancer (3) . PIM3 kinase has been found aberrantly expressed in malignant lesions of endoderm-derived organs, liver and pancreas and also in Ewing's sarcoma (3) . Recent studies have correlated PIM1 kinase with chemoresistance in prostate cancer cells, which is a common occurrence in more aggressive, hormone-refractory prostate cancers (19, 20) . PIM1 kinase has also been linked to hypoxia-promoted genetic instability in solid tumours facilitating cell survival, resulting in tumours with a more aggressive phenotype (21) .
Although the PIM kinases have been identified as oncogenes in transgenic models, by themselves they are only weakly transforming. However, they have been shown to greatly enhance the ability of c-myc to induce lymphomas (11, 12, 22, 23) . It is understood that mere overexpression of MYC induces an apoptotic response, which has to be overcome to permit oncogenesis (11, 14, 15) . PIM kinases (PIM1 and PIM2) have been shown to counteract this MYC-induced apoptosis by phosphorylating MYC, thus increasing its protein stability, and consequently its transcriptional activity (1) . The overexpression of either PIM1 or PIM2 in factor-dependent haematopoietic cells makes them resistant to apoptosis induced by interleukin-3 withdrawal (24) (25) (26) , probably through phosphorylation and inactivation of the proapoptotic protein BAD (25, 27) . PIM kinases mediate their physiological activities through phosphorylation of a wide range of cellular substrates which, due to the functional redundancy of the PIM kinase family, greatly overlap. Previously described phosphorylation targets include SOCS-1 (28), runt-related transcription factor 1 (RUNX1) and RUNX3 (29) ; cell cycle regulators such as p21 waf1 and p27 kip1 CDK inhibitors (30, 31) , CDC 25A phosphatase (32) and the kinase cTAK/MARK3/Par1A, and transcriptional repressors (HP1), activators (NFATc1 and c-MYB) and coactivators (p100 (33) (34) (35) (36) (37) ). More recently, PIM2 has been shown to phosphorylate the ribosomal protein 4E-BP1, causing its dissociation from eIF-4E, which may affect protein synthesis as eIF-4E is a rate-limiting factor (28) . Interestingly, several of the mentioned substrates are shared with AKT kinases, and PIM and AKT often phosphorylate the same residues (1,2). Interestingly, animals deficient in Pim1 are viable and show only a minor defect in haematopoiesis (38, 39) , suggesting that PIM1 contributes to haematopoietic cell growth and survival, although its role is probably secondary to other signalling pathways. More importantly, mice which are lacking expression of Pim1, Pim2 and Pim3 are viable and fertile, although they show a profound reduction in body size at birth and throughout postnatal life (7) . In addition, the in vitro response of distinct haematopoietic cell populations to growth factors is severely impaired. These results indicate that members of the PIM protein family are important but dispensable factors for growth factor signalling (7) .
Together, these studies suggest that PIM kinases may play a distinct role in tumour formation in vivo, implying that they may be novel targets for cancer therapy (40) .
However, very little is known about the relative contribution of the different isoforms to the tumourigenesis in vivo, and how their individual inhibition might affect tumour growth. Taking advantage of genetically modified mice, we explored whether the inhibition of specific isoforms is required to prevent tumour growth either in vitro, in mouse embryonic fibroblasts (MEFs) or in vivo in tumours induced by 3-methylcholanthrene (3MC) carcinogenic treatment.
Materials and methods

Culture conditions and cell line conservation
All cell lines were grown in Dulbecco's modified Eagle's medium supplemented with glutamine (Sigma/Gibco), 10% fetal bovine serum (Sigma/Genycell), 40 U/ml penicillin, 40 U/ml streptomycin and 1 µg/ml fungizone (Gibco/ Invitrogen), further referred to as complete medium. Cells were grown on 10 cm ø plates and split when a confluent monolayer of cells was observed. Retroviral infection of cells was performed as described previously (41) . Selection of transfected or infected cells was carried out with 2 µg/ml puromycin.
Generation of MEFs
MEFs were generated from mouse embryos (day 12.5) of Friend virus B wild-type (WT) mice and genetically modified mice for Pim1, 2 and 3. After eliminating the head and liver (which were lysed and used for genotyping), the embryo was mechanically disaggregated and trypsinized for 10 min at 37°C. The adherent cells were grown in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal bovine serum from Sigma and 1% penicillin G sulphate/streptomycin on 10 cm ø culture plates. Cells were immortalized using the 3T3-protocol. Once immortalized, one clone of each genotype was selected for further analysis.
3T3-protocol was performed as described previously (42) . Briefly, every 3 days, cells were trypsinized, counted and replated at 1 million live cells per 10 cm plate.
Proliferation, growth under low serum conditions, foci formation, saturation density and clonability assays were performed as described previously in refs (43, 44) .
Maintenance of mouse colonies
All animals were kept in the Centro Nacional de Investigaciones Oncológicas animal facility according to the norms for animal welfare.
Genotyping of mouse lines
Pim1, 2 and 3 knockout (KO) mice were genotyped by PCR using the standard PCR protocol for transgenic mice and PCR protocols provided by M. Narwijn (Netherlands Cancer Institute, Netherlands) for the triple KO-Pim mice (7) . Subsequently, Pim mutants (KO) were identified by PCR: the Pim1 alleles were detected using Pim1 and Neo primers (Pim1For, 5ʹAAGCACG-TGGAGAAGGACCG-3_; Pim1Rev, 5ʹGACTGTGTCCTT GAGCAGCG-3_; NeoA, 5ʹCGTCCTGCAGTTCATTCAGG-3_), the Pim2 alleles with Pim2 and Pgp primers (Pim2For, 5ʹCACCGCGTCACGGATAGACG-3_; Pim2Rev, 5ʹCCCACCTTCCACAGCAGCG-3_; HygroFor, 5_AGCACTCGTCC GAG-GGCAAAGG-3_; Pim2Rev2, 5_-CACGGTGGACCAGCCTAGC-3_) and the Pim3 alleles with Pim3 and lacZ primers (Pim3Sp1, 5ʹCTGGACC AAATT-GCTGCCCAC-3_; Pim3Sp4, 5ʹGGATCTCTGGTTCAAGTATCC3_; LacZ1, 5ʹCGTCACACTACGTCTG-AACG-3_; LacZ2, 5ʹCGACCAGATGATCAC-ACTCG-3_).
mRNA expression
We analysed the expression of the Pim1, Pim2 and Pim3 transcripts in tumours by reverse transcription-PCR (RT-PCR). For this, total RNA was isolated from 3MC-induced sarcoma using TriZol (Gibco BRL), treated with DNase, and reverse transcribed with random hexamer primers (Promega) and avian myeloblastosis virus-reverse transcriptase (Roche). The cDNA was amplified in a single PCR using for Pim1 primer combinations (mPim1fwRT, 5ʹATGC-TCCTGTCCAAGATCAACTC-3_; Pim1revRT, 5ʹCTCCAGGATCAGG ACGAAACTGT-3_) for Pim2 (Pim2fwRT, 5ʹATGTTGACCAAGCCTCTG-CAGG-3_; Pim2revRT, 5ʹGCTCAAGGACCAGCATGAAGC-3_) and for Pim3 (Pim3fwRT, 5ʹATGCTGCTGTCCAAGTTCGGCT-3_; Pim3revRT, 5ʹGCT CGAACCAGTCCAGCAAGC-3_). As a control, mouse Gapdh was amplified in the same PCR using the primers GapdhFw (5ʹAAGGTCGGTGT-GAACGGATT-3_) and GapdhRev (5ʹTTGCTGGGGTGGGTGGTC-3_).
Carcinogenesis induced by 3MC
The carcinogen 3MC was dissolved in sesame oil (Sigma) at a final concentration of 10 mg/ml. The solution was heated up to 100°C for 1 h and mixed vigorously in order to completely dissolve the 3MC. Mice of 3-5 months of age were injected with 1 mg (100 µl) of 3MC once into the right hind leg and later examined twice a week. The mice were killed when the tumour reached 1 cm in diameter.
Necropsy and pathological analysis
Once killed, tissues for histological and molecular analysis were taken. Tissues meant for molecular analysis were frozen in carbonic ice and later stored at −80°C. Tissues for histological analysis were fixed in 10% formalin for 24 h, dehydrated and embedded in paraffin. Two micrometre cuts were taken off and dyed with haematoxylin and eosin or different primary antibodies: KI-67 prediluted (Master Diagnostica-0003110QD), Caspase 
Statistical data analysis
The computer program GraphPad Prism was used for all statistical analysis. To determine the statistical significance of tumour growth and bone invasion, one-way Student's t-test analysis was used. To determine the statistical significance of survival curves, the Mantel-Cox test was used.
Analysis of protein expression
The cells were washed twice in 1× phosphate-buffered saline, pelleted for 30 s at 14 000g and lysed in lysis buffer (Tris-HCl pH 7.5 50 mM, NP40 1%, glycerol 10%, NaCl 150 mM, complete protease inhibitor cocktail, 2 mM; Roche). Total protein from frozen mouse tissue (maintained at −80°C) was extracted after mechanical tissue disintegration using a sterile plastic piston in 1 ml lysis buffer. After centrifugation, supernatant protein extracts were aliquoted and stored at −80°C until use.
The amount of protein was determined by Bradford assay using bovine serum albumin as a standard. The appropriate protein quantity was dissolved in Laemmli buffer (Tris-HCl pH 6.8 62.5 mM, glycerol 10%, sodium dodecyl sulphate 1%, 2-mercapto ethanol 5% and bromophenol blue 0.0025%) and the proteins were separated in sodium dodecyl sulphate-PAGE gels (12%) before they were blotted onto Nitrocellulose Transfer membrane (Whatman -Protrans). The proteins were visualized via the Odyssey LI-COR system. The primary antibodies used were p53 1:1000 (Cell Signalling-2524), 4E-BP 1:1000 (Cell Signalling-9644), p4E-BP Thr37/46 1:1000 (Cell Signalling-9459), Gsk3β 1:1000 (BD Transduction-610202), pGsk3β 
Results
Effect of Pim loss in vitro
First, we generated MEFs from double Pim2/3 KO mice (DKO) or from mice lacking all three isoforms (TKO), in parallel with isogenic WT MEFs. To that end, we first immortalized MEFs from all genotypes. MEFs followed similar senescence kinetics and were immortalized with similar frequency irrespective of the genotype (data not shown). Once immortalized, MEFs were grown in media with optimal (10%) or suboptimal (0.5 and 2%) concentrations of serum ( Figure  1A ). At 0.5%, all MEFs showed very slow growth but no apoptosis, irrespective of the Pim isoforms that were expressed. At 2% of serum, we observed clear differences in the growth of MEFs depending on the genotype. TKO MEFs showed poor growth compared with WT MEFs, while DKO MEFs showed intermediate proliferation. The differences between DKO and TKO increase in respect to WT MEFs at 10% serum concentration ( Figure 1A) .
However, these differences were more dramatic in MEFs infected with virus-carrying oncogenic H-RAS V12 ( Figure 1B ). To that end, MEFs were infected with viruses carrying oncogenic H-RAS V12 or empty vectors. MEFs carrying H-RAS V12 were seeded as before in optimal or suboptimal growth conditions. At low serum doses, all MEFs, irrespective of their genotype, were unable to grow, showing high apoptosis. However, at 10% serum, WT MEFs expressing H-RAS V12 grew fast, while TKO and DKO MEFs grew initially but stopped growth with high apoptosis after the initial rounds of duplication ( Figure 1B) .
These data suggest that loss of PIM kinases might rend cells resistant to oncogenic transformation. To examine this hypothesis, we transfected WT, TKO and DKO MEFs with oncogenic H-RAS V12 and measured the number of foci formed. In this assay, combined loss of Pim2 and Pim3 is sufficient to block the foci formation induced by H-RAS V12 ( Figure 1C ). TKO MEFs grow forming a nonhomogeneous layer of cells, making it difficult to assess the foci formation.
To compare the data among the three genotypes and to explore the functional relevance of each individual PIM kinase in vitro, we decided to perform saturation density analysis. Immortal non-transformed MEFs have contact inhibition stopping growth once the monolayer is formed. However, oncogenically transformed MEFs continue growth after the monolayer is formed increasing the density of cells. We observed that the growth of DKO and specially TKO MEFs is . After selection, the different mass cultures were seeded and grown under 10% serum conditions until they reach confluence. Then, the cells were cultured in the same plate for one more week changing media every 2 days. After this time, cells were fixed, stained and the number of cells counted as a relative measure of absorbance (Materials and methods).
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lower than the growth of WT cells ( Figure 1E, lane C) . To compare the individual role of each kinase isoform in this assay, we expressed ectopically PIM1, PIM2 or PIM3 into WT MEFs, or MEFs lacking Pim2 and 3 (DKO) or lacking all three Pim isoforms (TKO). We observed that the increased expression of one isoform of PIM kinases into Pim containing MEFs (WT or DKO) does not alter significantly the saturation density of control cells ( Figure 1E, hatched bars) . However, in TKO MEFs, the recovery of Pim activity is sufficient to alter growth forming monolayer (data not shown) and increase the saturation density to levels similar to DKO cells ( Figure 1E, hatched  bars) . Furthermore, we measured the response of these cells to oncogenic transformation with H-RAS V12 . Oncogenic transformation with H-RAS, as expected, increases saturation density in WT MEFs, and the increase in one of the PIM isoforms does not seem to provide any advantage ( Figure 1E, solid bars) . In DKO cells expressing only Pim1, H-RAS does not increase saturation density, correlating with the results observed in Figure 1C . However, expressing H-RAS in MEFs that recovered the expression of two isoforms increase the saturation density to levels similar to WT cells ( Figure 1E, solid bars) . Finally, in TKO MEFs, the expression of H-RAS does no increase the saturation density in any of the cultures expressing only one isoform ( Figure 1E , solid bars). Our data indicate that at least the expression of two isoforms is necessary to provide ability to support oncogenic transformation. Only overexpression of PIM1, in the absence of Pim2 and 3 seems to provide some benefit in the presence of oncogenic H-RAS.
Effect of Pim loss in vivo after carcinogenic treatment
To evaluate whether PIM kinases play a relevant role in the process of sarcomagenesis induced by the carcinogen 3MC, we performed intramuscular injection of 3MC, which produced sarcoma tumours with an onset of tumour growth at approximately 98 days after inoculation. An in-deep account of the time to first tumour observation showed that WT tumours appear in average around 12-20 days earlier than DKO or TKO tumours, respectively. Since this first observation, tumours took an average of 9 days in WT mice to reach the final volume size of 1.7 cm 3 (ca. 10% of mouse weight), indicating a rapid growth of these tumours (Figure 2A ). However, in DKO it took an average of 21 days to reach the same size, while in TKO mice the tumours reached this size in 32 days after onset of tumour growth (Figure 2A ). This significant time increase indicated that lack of Pim2 and Pim3 kinases is sufficient to produce a significant delay in the growth of the sarcoma. Additional loss of Pim1 only produces an additional marginal delay. This slow sarcoma growth rate was reflected in the survival of the mice. DKO and TKO mice treated with 3MC died significantly later than WT mice ( Figure 2B ). This was most probably due to the slower growth rate of the tumour.
To confirm the relative contribution of each isoform to sarcomagenesis, we analysed whether the tumour generated by the carcinogenic treatment in each mouse derived from true KO cells, or whether they maintained the relative expression of the Pim isoforms. We collected mRNA from all the tumours and evaluated the presence of individual Pim isoforms' RNA expression ( Figure 2C ). We observed that the sarcoma originated in WT mice maintained expression of all three pim isoforms, while DKO expressed only pim1. Tumours originated in TKO mice did not express any pim isoform.
The analysis of the sarcomas from all three genotypes showed that 3MC activated p53 in DKO and TKO MEFs to a similar extent to in WT MEFs (Figure 3A) , which was expected from the DNA-damage activity of 3MC. As a consequence, all tumours carried mutated p53 ( Figure 3B ). All tumours, independently of the genotype, showed similar levels of KI67, as it corresponds to fast-growing tumours but with very heterogeneous distribution ( Figure 3C ). This large variability among tumours precluded any conclusion from this marker. However, the percentage of Cyclin D1-positive cells, another proliferation marker, showed that the number of proliferating cells in WT tumours was higher than in DKO and TKO mice ( Figure 3C and data not shown). Although this increase was not statistically significant due to the variability among tumours, it showed a clear trend that tumours of DKO and TKO mice were less proliferative. The reduced levels of Cyclin D1 might explain the reduced proliferation rate of the tumours. Similarly, all tumours contain Caspase 3 staining ( Figure 3C ). However, as in the case of KI67, the large variability among tumours precluded any conclusion regarding increased apoptosis.
To study the mechanism implicated in the reduction of growth rate in pim-deficient tumours, we analysed the relative levels of proteins that are direct or indirect targets of PIM kinases and might be involved in slowing the cell cycle. PIM kinases phosphorylate p27 kip1 , inducing its degradation (31) , and might alter the protein translation through 4EBP-1 (45, 46) . On the other hand, Pim3-induced tumours show increased levels of Cyclin D1 (47) and active Gsk3β alters Cyclin D1 stability by enhancing its degradation (48) . Furthermore, since AKT has been reported to be situated downstream of Pim in some models (49), we also measured the phosphorylation status of these proteins (Figure 4) .
We did only see minimal differences in 4E-BP1 phosphorylation among the tumours of the different genotypes, with reductions in the DKO and TKO tumours ( Figure 4A and B) . We observed also slightly lower levels of pErk and p27 kip1 in most DKO and all TKO tumours we analysed ( Figure 4A and B) . However, the analysis of Gsk3β For western blot analysis of direct or indirect PIM kinase targets, whole cell protein was extracted from freshly resected tumours from mice and levels of different proteins were determined by western blot. Western blot of the phosphorylated proteins recognizes phosphorylation at the following residues: p4E-BP at Thr37/46, pGsk3β at Ser9, pAkt at Ser473 and pErk1/2 at Thr202/Tyr204. Two tumours per genotype are shown. (B) Quantification of the levels of the different proteins analysed. Each graph shows the relative levels of the protein indicated p4E-BP (phosphorylated protein at Thr37/46 related to total p4E-BP), pGsk3β (phosphorylated Gsk3β at Ser9 related to total pGsk3β), pAkt (phosphorylated Akt at Ser473 related to total Akt), pErk1/2 (phosphorylated Erk1/2 at Thr202/Tyr204 related to total Erk1/2) and p27 (total p27 related to tubulin). Graphs show average and standard deviation of levels in all tumours analysed, as indicated in text. (C) Western blot analysis of pGsk3β phosphorylation at Ser9 in MEFs. Whole cell protein was extracted from MEFs and levels of proteins were determined by western blot. One representative MEF clone per each genotype is shown.
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phosphorylation at ser9 (inactive form) by western blot showed that this residue is not phosphorylated in most DKO and all TKO tumours ( Figure 4A and B) . Only one out of five DKO tumours showed phosphorylated Gsk3β at ser9, while none of the analysed TKO tumours showed ser9 Gsk3β phosphorylation. In contrast, AKT phosphorylation did not show significant variations among tumours ( Figure 4A and B), indicating that the effect on Gsk3β is not due to inactive Akt in Pim-null tumours. Levels of other proteins such as MAP kinases did not show variations in the tumours from different genotypes either ( Figure 4A ). To explore whether that effect on ser9 Gsk3β phosphorylation was a general effect due to Pim absence we analysed Gsk3β in MEFs from all three genotypes ( Figure 4C ). All MEFs showed similar content on Gsk3β and Gsk3β phosphorylated at Ser9, indicating that loss of Gsk3β phosphorylation at Ser9 occurs during the tumourigenic process.
Loss of PIM kinases reduces bone invasion by sarcoma
One interesting property in our 3MC-induced sarcomas was the microscopically observed bone invasion ( Figure 5A ). Sarcoma cells are able to degrade bone and invade bone marrow. In over 80% of tumours induced in WT animals, we detected bone invasion by these sarcomas ( Figure 5B ). However, the microscopic analysis showed that lack of Pim2 and 3 reduced the percentage of sarcomas invading bone to 31%. Lack of all three isoforms reduced bone invasion to 17% ( Figure 5A ), confirming the relevance of these kinases in the process. Furthermore, we have detected that these tumours have reduced expression of MMP9 metaloproteinase correlating with the decreased bone invasion we observed ( Figure 5C ).
Discussion
PIM kinases are an active target for drug discovery research, with most compounds focused on the PIM1 isoform due to its known implications in tumourigenesis. However, especially in vivo, little is known regarding the specific contribution of each isoform to tumourigenesis. Taking advantage of genetically modified mice, we explored whether the inhibition of specific isoforms is required to prevent sarcomas induced by 3MC carcinogenic treatment. We found that absence of Pim2 and Pim3 greatly reduced sarcoma growth to a similar extent to the absence of all three isoforms. Similar results were obtained in MEFs derived from these KO mice, where double Pim2/3 KO MEFs already showed reduced proliferation and were resistant to oncogenic transformation. To block bone invasion by the tumour, although the absence of all three isoforms is necessary to achieve the maximum effect, depletion of Pim2 and Pim3 seems to be sufficient to achieve a large reduction of the invasive effect.
We observed that sarcomas arising from Pim-defective mice grow significantly slower, correlating with reduced proliferation markers, suggesting reduced proliferative capacity. It has been shown that PIM1 phosphorylates CDC25A, thereby increasing its phosphatase activity and the activity of Cyclin D1-associated kinases, which results in cell cycle progression (32) . The CDC25C-associated kinase 1 (C-TAK1) is a potent inhibitor of CDC25C, a protein that actively promotes cell cycle progression at the G2/M phase. By phosphorylating C-TAK1, PIM1 inhibits its activity and eventually advances the cell cycle (50) . Furthermore, PIM1 can phosphorylate p21 waf1 , another molecule involved in cell cycle progression, at its threonine residues, resulting in its relocation to the cytoplasm and enhancing its protein stability (30, 51) . These effects are associated with increased cell proliferation. Thus, it is tempting to speculate that PIM can promote cell cycle progression and thus eventually contributes to carcinogenesis by modulating the function of molecules that regulate cell cycle progression.
Our data showed a reduction of Cyclin D1 in Pim-null tumours correlating with a decrease in the proliferative capabilities of these tumours. Furthermore, we also observed a partial inhibition of 4E-BP1 phosphorylation and slightly lower levels of pErk in the DKO and TKO tumours ( Figure 4A and B) . It is possible that the addition of those mild effects contributed to reduced proliferation, slowing the tumour growth rate.
However, the most important mechanistic feature observed in our model is the loss of Gsk3β phosphorylation at Ser9 (inactive form) in most tumours of Pim-depleted mice, but not in MEFs of the same genotype. Absence of Gsk3β Ser9 phosphorylation will maintain high Gsk3β activity, reducing cell cycle transition and glucose metabolism (48, 52) . This residue has been shown to be phosphorylated by Akt (48) . It is possible that Akt activation lies downstream of Pim, as has been described previously (49) . Therefore, loss of Pim might abolish Akt activation and subsequent Gsk3β phosphorylation. However, analysis of tumours showed similar levels of Akt activation in Pim-null tumours, suggesting that Gsk3β Ser9 residue phosphorylation depends on a kinase different from Akt. It is possible that Pim itself phosphorylates Gsk3β at Ser9 and inactivates the protein, since Akt and Pim share many protein substrates (1-3) . On the other hand, Gsk3β is also a substrate of PP2A (53) (54) (55) , which has been recently described as a target of PIM kinases (56) . Therefore, loss of PIM kinases might increase the levels of PP2A, leading to Gsk3β dephosphorylation. Furthermore, loss of Pim expression might increase levels of PP2A activity, which may mediate the levels of c-Myc and the phosphorylation of proteins needed for increased protein synthesis. Both of these changes could have a significant impact on tumour growth (56) . Whichever it is the mechanism, it occurs only as a consequence of the tumourigenic process in the absence of Pim, since Pim-null MEFS maintain Gsk3β phosphorylation at Ser9 residue, suggesting that there is no redundancy in this Gsk3b phosphorylation, and therefore, this protein can be a good therapeutic target for invasion in Pim-dependent tumours.
One of the most interesting pieces of data found in our work is the correlation of PIM kinases with the process of bone invasion in vivo. Absence of PIM kinases blocks the process of bone invasion induced by the 3MC-induced sarcoma, and the genes seem to act in an additive manner, since absence of Pim2 and Pim3 produces only a partial effect and the absence of all three is necessary to achieve the maximum effect. In agreement with our data, siRNA interference of PIM1 and PIM2 reduced PC3 migration in vitro by around 50% while inhibition of all three PIM kinases by DHPCC-9 (a specific pan PIM inhibitor) reduced migration of PC3 in vitro by 90% (57) . In addition, overexpression of any PIM family member has the opposite effects by enhancing cell motility (57) . Silencing of PIM3 was also reported to reduce endothelial cell spreading, migration and vascular tube formation, further supporting that this kinase can stimulate metastatic and/or angiogenic potential of cancerous cells (58) . In addition, PIM1, but not PIM2, was shown to regulate homing and migration of bone marrow cells, possibly via phosphorylation-mediated modification of CXCR4 expression in the cell surface (59) . The substrates and signalling pathways regulated by PIM kinases, that contribute to enhancing the motility of adherent cancer cells remain, however, to be elucidated. Recently, the NFAT transcription factors, identified as PIM targets (35) have been implicated in tumour cell migration and invasion (60) . Since NFAT is also a target of GSK3β, it is tempting to speculate that lack of ser9-Gsk3β phosphorylation in Pim-null tumours contributes to reduced migration by maintaining low levels of NFAT activation.
Besides our work, several other features justify the use of PIM as a cancer target; its overexpression in various types of tumours, its role in the regulation of pathways considered relevant in cancer, as well as the fact that blocking PIM1 function by introduction of dominant negative PIM1 sensitizes pancreatic cancer cells to apoptosis induced by glucose deprivation under hypoxia (21) . Moreover, dominant negative PIM1 reduces tumourigenicity in pancreatic cancer cells and HeLa xenograft mouse models. These and other data have led to the synthesis of PIM inhibitors that have recently entered clinical trials.
Inhibitors of PIM are of interest as potential therapeutic agents (5, 19, 45, 61, 62) ; therefore, the understanding of the process that can be targeted by PIM inhibition is of great importance to define the potential activity of these compounds. However, there is some degree of redundancy among PIM kinases that should be studied while defining the specificity of the pharmacological compounds. The levels of expression of the different PIM family members vary among tumour types. PIM1 and PIM2 are mostly overexpressed in leukaemia and lymphomas. PIM1 is also overexpressed in some solid tumours such as prostate, pancreas and colon. PIM3 overexpression has been observed in melanoma, pancreatic and gastric tumours. The possibility of overlapping substrates and the potential compensatory nature of the different PIM family members as demonstrated by the triple KO mouse model suggests that the inhibition of all isoforms may be more effective than targeting individual isoforms. In our genetic model, higher activity is achieved in the absence of all family members although sarcoma growth is already significantly reduced in PIM2-and 3-depleted mice.
Since both the PI3K and PIM signalling pathways converge on the regulation of many signalling proteins that are common for AKT and PIM, it is possible that some redundancy among these pathways also occurs in tumours. In fact, It has been described that PIM inhibitors synergize with mTOR of PI3K inhibitors (45, 46) . Dual treatment with the compounds resulted in decreased phosphorylation of 4E-BP1 and BAD proteins as well as an increase in apoptosis. These data suggest that a combination of drugs that selectively target PI3K/AKT and PIM may have potential in treating tumours. 
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